LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

30.6 23.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.72

Max

30.95

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+90.82% upside

Dividenden
By Dow Jones
Volgende Winsten	4 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	111M 1.6B
Vorige openingsprijs	6.81
Vorige sluitingsprijs	30.6

Nieuwssentiment

By Acuity

50%

167 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 feb 2026, 23:25 UTC

Populaire aandelen

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Winsten

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Marktinformatie

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Winsten

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Winsten

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Winsten

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Winsten

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Winsten

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Marktinformatie

Winsten

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Marktinformatie

Winsten

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Winsten

Acquisities, Fusies, Overnames

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Marktinformatie

Winsten

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Winsten

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Winsten

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Winsten

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Winsten

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

90.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 47.4 USD 90.82%

Hoogste 62 USD

Laagste 24 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

167 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.